

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Miri Seiberg, et al.
Serial No. : (Divisional of 09/206,249) Art Unit: 1651
Filed : March 7, 2002 Examiner:
For : METHOD FOR REGULATING PHAGOCYTOSIS

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

This Preliminary Amendment is respectfully submitted in order to conform the claims with regard to the restriction requirement rendered in the above-identified parent application, Serial No. 09/206,249. A Petition for Extension of Time was submitted in conjunction with the parent application. Kindly amend the above-identified patent application as follows:

IN THE SPECIFICATION:

Kindly add the following:

--This application is a divisional application of parent patent application U.S. Serial No. 09/206,249, which is hereby incorporated herein by reference.--

IN THE CLAIMS:

Kindly amend the claims as follows:

5. The composition of claim 1, wherein the composition comprises an agent which activates the PAR-2 pathway.
8. The composition of claim 2, wherein the composition comprises an agent which inhibits the PAR-2 pathway.
9. The composition of claim 2, wherein the composition comprises an agent selected from the group consisting of a soybean derivative and a serine protease inhibitor.
11. The composition of claim 1, wherein the appropriate cells are PAR-2-expressing cells.

16. The composition of claim 1, wherein the disorder is selected from the group consisting of a skin disorder, an immune system disorder, an inflammatory disorder, a respiratory disorder, and a central nervous system disorder.
22. The composition of claim 1, wherein the mammal is a human.
30. The method of claim 29, wherein the agent is selected from the group consisting of soybean paste, compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.
31. The method of claim 23, wherein the mammalian cell is a PAR-2-expressing cell.
36. The method of claim 23, wherein the mammalian cell is a human cell.
41. The method of claim 37, wherein the agent activates the PAR-2 pathway.
44. The method of claim 38, wherein the agent inhibits the PAR-2 pathway.
45. The method of claim 38, wherein the agent is selected from the group consisting of a soybean derivative and a serine protease inhibitor.
47. The method of claim 37, wherein the appropriate cells are PAR-2-expressing cells.
52. The method of claim 37, wherein the disorder is selected from the group consisting of a skin disorder, an immune system disorder, an inflammatory disorder, a respiratory disorder and a central nervous system disorder.
58. The method of claim 37, wherein the mammal is a human.
59. An article of manufacture for administering to a mammal the composition of matter of claim 1, comprising a solid delivery vehicle having the composition operably affixed thereto.
65. The article of claim 64, wherein the agent is selected from the group consisting of soybean paste, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.

REMARKS


This Preliminary Amendment is respectfully submitted in order to conform the claims with regard to the restriction requirement rendered in the above-identified parent application, Serial No. 09/206,249. A Petition for Extension of Time was submitted in conjunction with the parent application.

A marked-up copy of the claims as amended appears in the Appendix hereto. Claims 5, 8, 9, 11, 16, 22, 31, 36, 41, 44, 45, 47, 52, 58 and 59 have been amended without prejudice in order to eliminate multiple dependencies. Leave to introduce the claimed subject matter again is respectively reserved. Claims 30 and 65 have been amended in order to delete reference to

"soybean milk", a species which is currently being prosecuted in the parent patent application,
U.S. Serial No. 09/206,249.

Consideration of the claims as amended is respectfully requested. An early allowance is
earnestly solicited.

Respectfully submitted,


Andrea L. Colby
Attorney for Applicants
Reg. No. 30,194

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2792
March 7, 2002

APPENDIX – MARKED-UP CLAIMS

5. (Amended) The composition of claim 1 [or 3], wherein the composition comprises an agent which activates the PAR-2 pathway.
8. (Amended) The composition of claim 2 [or 4], wherein the composition comprises an agent which inhibits the PAR-2 pathway.
9. (Amended) The composition of claim 2 [or 4], wherein the composition comprises an agent selected from the group consisting of a soybean derivative and a serine protease inhibitor.
11. (Amended) The composition of claim 1, [2, 3 or 4,] wherein the appropriate cells are PAR-2-expressing cells.
16. (Amended) The composition of claim 1, [2, 3 or 4,] wherein the disorder is selected from the group consisting of a skin disorder, an immune system disorder, an inflammatory disorder, a respiratory disorder, and a central nervous system disorder.
22. (Amended) The composition of claim 1, [2, 3 or 4,] wherein the mammal is a human.
30. (Amended) The method of claim 29, wherein the agent is selected from the group consisting of [soybean milk,] soybean paste, compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.
31. (Amended) The method of claim 23 [or 24], wherein the mammalian cell is a PAR-2-expressing cell.
36. (Amended) The method of claim 23 [or 24], wherein the mammalian cell is a human cell.
41. (Amended) The method of claim 37 [or 39], wherein the agent activates the PAR-2 pathway.
44. (Amended) The method of claim 38 [or 40], wherein the agent inhibits the PAR-2 pathway.
45. (Amended) The method of claim 38 [or 40], wherein the agent is selected from the group consisting of a soybean derivative and a serine protease inhibitor.
47. (Amended) The method of claim 37, [38, 39 or 40,] wherein the appropriate cells are PAR-2-expressing cells.

52. (Amended) The method of claim 37, [38, 39 or 40,] wherein the disorder is selected from the group consisting of a skin disorder, an immune system disorder, an inflammatory disorder, a respiratory disorder and a central nervous system disorder.

58. (Amended) The method of claim 37, [38, 39 or 40,] wherein the mammal is a human.

59. (Amended) An article of manufacture for administering to a mammal the composition of matter of claim 1, [2, 3 or 4,] comprising a solid delivery vehicle having the composition operably affixed thereto.

65. (Amended) The article of claim 64, wherein the agent is selected from the group consisting of [soybean milk,] soybean paste, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.